<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276298</url>
  </required_header>
  <id_info>
    <org_study_id>RCT Haemorrhoidectomy</org_study_id>
    <nct_id>NCT04276298</nct_id>
  </id_info>
  <brief_title>Topical Analgesia Post-Haemorrhoidectomy</brief_title>
  <official_title>A Prospective, Multicentre, Double-Blinded Randomised Controlled Trial Comparing Topical Metronidazole, Diltiazem and Lidocaine on Post-Operative Pain Following Excisional Haemorrhoidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Auckland, New Zealand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Symptomatic haemorrhoids, or piles, have significant effects on quality of life. The&#xD;
      treatment for advanced disease is surgical excision (haemorrhoidectomy) which is extremely&#xD;
      effective. However, pain following haemorrhoidectomy is known by all to be a miserable&#xD;
      experience and current treatment is not very effective. We have formulated a new cream&#xD;
      treatment which targets three theorised mechanisms of pain after haemorrhoidectomy. We will&#xD;
      test the effectiveness of the treatments with a multi-centred randomised controlled factorial&#xD;
      trial with four parallel double-blinded arms containing different combinations of the active&#xD;
      agents. The outcomes include pain scores, amount of analgesia required and time to return to&#xD;
      work. The results of our study could provide evidence of an effective treatment for post&#xD;
      haemorrhoidectomy pain. The treatment may provide considerable benefit to patients undergoing&#xD;
      this surgical procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This will be a patient-and-investigator blinded factorial randomised trial with&#xD;
      four parallel groups. Participants in all four groups will be instructed to apply cream 3&#xD;
      times a day for 7 days after surgery. A standard analgesia prescription will be provided with&#xD;
      laxatives as per routine care. Patients will be provided a questionnaire to complete and&#xD;
      return on day 14.&#xD;
&#xD;
      Random Sequence Generation: Computer generated sequence allocating patients to a 1:1:1:1&#xD;
      ratio using permuted block randomisation in blocks of 12.&#xD;
&#xD;
      Allocation Concealment: This randomisation code will be seeded to the pharmacist to who will&#xD;
      package and label the cream according to a code. The creams will be indistinguishable to&#xD;
      which active ingredient they contain.&#xD;
&#xD;
      Assignment of intervention: Patients will be assigned in order according to the numbering of&#xD;
      the cream tubes by the blinded investigator.&#xD;
&#xD;
      Data recording: Data will be recorded on Redcap database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Parallel with 1:1:1:1 Allocation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double blinded trial, both participant and investigator are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores</measure>
    <time_frame>7 days</time_frame>
    <description>Measured by visual analog scale, 1-10cm, continuous, the higher the score, the worse the pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of analgesic use</measure>
    <time_frame>7 days</time_frame>
    <description>Morphine equivalent amount</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return to work</measure>
    <time_frame>14 days</time_frame>
    <description>Day post-operation when the patient returns to work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on bowel motion: Visual Analog Scale</measure>
    <time_frame>7 days</time_frame>
    <description>Measured by Visual Analog Scale, continuous 1-10cm, the higher the score, the worse the pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Rates of Bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-admission</measure>
    <time_frame>30 days</time_frame>
    <description>Rates of Re-admission to hospital,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat Prescription</measure>
    <time_frame>30 days</time_frame>
    <description>Rates of Repeat Prescription Requirement</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Hemorrhoid Pain</condition>
  <condition>Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>Metronidazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A receiving 10% metronidazole cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole + Diltiazem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 10% + Diltiazem 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole + Lignocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 10% + Lignocaine 4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole + Diltiazem + Lignocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole 10% + Diltiazem 2% + Lignocaine 4%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole cream</intervention_name>
    <description>10% metronidazole applied rectally</description>
    <arm_group_label>Metronidazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole and Diltiazem cream</intervention_name>
    <description>Combination Metronidazole and Diltiazem applied rectally</description>
    <arm_group_label>Metronidazole + Diltiazem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole and Lidocaine cream</intervention_name>
    <description>Combination metronidazole and lignocaine applied rectally</description>
    <arm_group_label>Metronidazole + Lignocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole, Diltiazem and Lidocaine cream</intervention_name>
    <description>Combination of all active agents tested applied rectally</description>
    <arm_group_label>Metronidazole + Diltiazem + Lignocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥16&#xD;
&#xD;
          -  All patients undergoing excisional haemorrhoidectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;16,&#xD;
&#xD;
          -  history of chronic pain,&#xD;
&#xD;
          -  drug allergy or idiosyncracies to any actives or excipients in&#xD;
&#xD;
          -  cream,&#xD;
&#xD;
          -  breastfeeding,&#xD;
&#xD;
          -  any medical history which is a contraindication to any of metronidazole, lidocaine, or&#xD;
             diltiazem including including:&#xD;
&#xD;
          -  sick sinus syndrome,&#xD;
&#xD;
          -  atrioventricular block,&#xD;
&#xD;
          -  hypotension,&#xD;
&#xD;
          -  heart failure and bradycardia.&#xD;
&#xD;
          -  concomitant medications which are contraindicated to metronidazole, lidocaine or&#xD;
             diltiazem.&#xD;
&#xD;
          -  patients already taking diltiazem.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew G Hill, MBChB, MD, EdD, FRACS, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Counties Manukau Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Jin, MBChB</last_name>
    <phone>6421 0235 1160</phone>
    <email>james.jin@auckland.ac.nz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Counties Manukau District Health Board</name>
      <address>
        <city>Auckland</city>
        <zip>1041</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Jin, MBChB</last_name>
      <phone>02102351160</phone>
      <email>james.jin@middlemore.co.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Auckland, New Zealand</investigator_affiliation>
    <investigator_full_name>Andrew G Hill, MBChB, MD (Thesis), EdD, FACS, FRACS</investigator_full_name>
    <investigator_title>Professor of Surgery, Head of School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will be shared when results become available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>When results are available for 12 months</ipd_time_frame>
    <ipd_access_criteria>email request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

